H. Res. 305 is a House resolution that expresses support for designating the fourth Wednesday in February as “Hypertrophic Cardiomyopathy Awareness Day.” The text compiles findings about HCM — including prevalence estimates, common symptoms, and recommended diagnostic tests — and calls for greater public awareness and for Americans to seek appropriate care.
Because it is a concurrent sense-of-the-House resolution, the bill creates no regulatory duties or funding streams. Its practical effect would be symbolic: it aims to raise the profile of HCM among clinicians, patients, and the public and to incentivize voluntary screening and education efforts by providers and advocacy organizations.
At a Glance
What It Does
The resolution formally supports establishing an annual awareness day (fourth Wednesday of February) for hypertrophic cardiomyopathy and records congressional findings about HCM’s prevalence, clinical presentation, diagnostic tests, and treatment options. It urges Americans to know their history and seek care but does not appropriate funds or change medical standards.
Who It Affects
Patients with HCM and their families, cardiology and genetic‑testing providers, patient advocacy organizations, and public health communicators are the primary audiences. Payers and frontline clinicians may see downstream impacts if awareness drives more diagnostic evaluations.
Why It Matters
The resolution targets a disease with a high estimated undiagnosed rate and symptoms that overlap with other conditions, so awareness could increase detection. Because it is nonbinding, the resolution’s influence will depend on how clinicians, health systems, insurers, and advocacy groups translate symbolic support into screening, education, or access initiatives.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
H. Res. 305 compiles a set of factual findings about hypertrophic cardiomyopathy (HCM) — a genetic cardiac disorder characterized by thickened heart muscle — and uses those findings to back an annual awareness day.
The text emphasizes that HCM can cause symptoms commonly seen in other cardiopulmonary disorders, which contributes to missed diagnoses, and it highlights both the scale of the potential undiagnosed population and the serious complications that can follow untreated disease.
The resolution lists diagnostic tools clinicians use to confirm HCM, naming echocardiography, cardiac MRI, and genetic testing, and it stresses the role of family history and clinical screening questions as first steps. It also references medical and surgical management options without prescribing specific care protocols; the purpose is to encourage conversation between patients and clinicians rather than to set clinical guidance.Because the document is a resolution rather than a statute, it contains no grant program, regulatory changes, or new obligations for health providers or insurers.
Its operational effect would be to signal congressional attention and to give patient groups and public health actors a clear date for awareness campaigns. Any changes in testing rates, referrals to cardiology, or insurer coverage would follow from voluntary actions by health systems, payers, and advocacy partners — not from the resolution itself.Finally, the resolution urges Americans to seek appropriate care and raises the profile of HCM among clinicians and the public.
That urging can catalyze education campaigns and possibly influence clinical practice patterns where clinicians and payers choose to respond, but the text leaves the scope, content, and financing of any follow‑on activities unspecified.
The Five Things You Need to Know
H. Res. 305 designates the fourth Wednesday in February as “Hypertrophic Cardiomyopathy Awareness Day.”, The resolution cites a U.S. prevalence range for HCM of roughly 1 in 200 to 1 in 500 and an estimate that 85% of U.S. cases may be undiagnosed.
It lists echocardiogram, cardiac MRI, and genetic testing as common diagnostic tools clinicians may use to confirm HCM and to evaluate family risk.
The text is a nonbinding House resolution that urges awareness and care but does not authorize funding, create new programs, or change clinical or insurance requirements.
The resolution urges health care providers to conduct screening questions and for patients to know their medical and family history to improve detection.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Congressional findings on HCM prevalence, symptoms, and risks
The preamble collects medical facts: HCM is described as an inheritable disease with thickened heart muscle, a prevalence estimate (1:200–1:500), and national case estimates ranging from 700,000 to 1,650,000. The clauses underline symptom overlap with other cardiopulmonary diseases and note elevated all‑cause mortality if untreated. These findings create the factual foundation the resolution uses to justify an awareness day, but they carry no regulatory force.
Documented diagnostic pathways and management options
Several ‘whereas’ clauses catalog diagnostic approaches — clinical screening questions, echocardiography, cardiac MRI, and genetic testing — and point to medical and surgical management options. Listing those modalities signals what the awareness day should promote (recognition, family history, referral for imaging/genetic evaluation), but the resolution does not define indications, referral thresholds, or coverage policies for these tests.
Support for the awareness day designation
Clause 1 is the symbolic core: the House expresses support for annually designating the fourth Wednesday of February as Hypertrophic Cardiomyopathy Awareness Day. The statement is ceremonial; it intends to encourage public observance and gives stakeholders a congressional‑backed date for outreach, commemoration, and education.
Acknowledgement of importance and urging Americans to seek care
Clauses 2 and 3 acknowledge the public‑health importance of HCM awareness and explicitly urge Americans to learn about the disease, know family history, and pursue appropriate care. Although phrased as exhortations, these clauses do not create clinical obligations, reporting requirements, or funding for awareness activities. Their practical effect depends on whether health systems, payers, and advocacy groups use the resolution as a catalyst for campaigns or expanded screening efforts.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People with undiagnosed HCM and at‑risk relatives — greater awareness could lead to earlier evaluation, diagnosis, and access to management that reduces complications.
- Patient advocacy organizations and disease groups — an official awareness day creates a focal point for fundraising, public education, and media outreach.
- Cardiology and genetic specialty clinics — increased referrals from primary care and community outreach could raise case detection and demand for specialty services.
- Public health communicators and professional societies — the resolution provides a clear annual date to coordinate campaigns, educational materials, and clinician guidance dissemination.
Who Bears the Cost
- Primary care clinicians and health systems — if awareness increases, clinicians will incur additional screening, counseling, and referral time without reimbursement changes spelled out in the resolution.
- Payers (private insurers and public programs) — higher rates of echocardiograms, cardiac MRIs, and genetic tests following awareness campaigns could increase claims unless covered as part of existing benefits.
- Patient advocacy groups and nonprofits — organizing national or local campaigns around the awareness day will require staff time and funding that the resolution does not provide.
- Patients without adequate insurance or in resource‑limited areas — increased calls for testing may expose disparities if advanced diagnostics remain inaccessible or unaffordable for some populations.
Key Issues
The Core Tension
The central dilemma is between the public‑health value of promoting early detection of a potentially life‑threatening inheritable condition and the risk that heightened awareness will drive costly, unevenly accessible testing and possible overdiagnosis; the resolution raises visibility but leaves unanswered who will pay for, regulate, and equitably implement any increased diagnostic activity.
The resolution is symbolic: it contains findings and exhortations but no appropriations, regulatory changes, or directives to federal agencies. That limits the text’s ability to solve the underlying problems it identifies — notably underdiagnosis and access to diagnostic testing.
Whether the awareness day leads to earlier diagnosis depends entirely on follow‑on actions by clinicians, health systems, payers, and advocacy groups.
Raising awareness creates a practical dilemma. On one hand, higher public and clinician awareness can prompt appropriate evaluations and life‑saving interventions.
On the other, it can increase demand for imaging and genetic testing that are costly and may yield incidental findings or false positives, generating downstream procedures and anxiety. The resolution does not specify screening criteria or prioritize funding for equitable access to advanced diagnostics, so increased detection could disproportionately benefit populations with better health coverage and geographic access to specialty care.
Implementation questions remain unanswered: who will lead coordinated national outreach, how success would be measured, whether insurers will expand coverage for increased genetic testing or imaging prompted by awareness campaigns, and how clinicians should translate awareness into evidence‑based screening. Those gaps make the resolution a starting signal rather than a policy solution; resolving the practical trade‑offs will require separate, substantive policy steps.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.